Literature DB >> 8067747

Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.

C O Onyeji1, D P Nicolau, C H Nightingale, R Quintiliani.   

Abstract

The duration of time that serum drug levels remain above the MIC (time above the MIC) for the pathogen has been shown to be the most significant parameter determining the efficacies of beta-lactam antibiotics. In the described study, we investigated the optimal time above the MIC of ceftibuten and cefaclor using a nonneutropenic mouse model of intra-abdominal infections caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Streptococcus pneumoniae. The abilities of the drugs to protect mice against the organisms were determined in mouse protection tests, and the doses were fractionated to produce various dosing regimens with different times above the MIC. All drug-organism combinations showed a significant correlation (r > 0.9) between drug efficacy and the time above the MIC. Also, with ceftibuten treatment, the different dosing regimens that produced equal times above the MIC resulted in the same efficacy, whereas with cefaclor, an apparent dose-dependent effect was observed. These results showed that for a 100% recovery from K. pneumoniae and E. coli infections, the optimal times above the MIC with ceftibuten treatment were 2.2 and 1.6 h, respectively. Relatively high doses of both antibiotics were required to ensure recovery from S. pneumoniae infections. In vitro time-kill studies demonstrated that cefaclor exhibits a marked inoculum effect against the pathogens, and there was a concentration-dependent killing at a large inoculum size. On the other hand, ceftibuten showed no inoculum effect. It is suggested that optimization of both dose and time above the MIC appears to be necessary for the treatment of S. aureus infections with cefaclor, and this may apply to other beta-lactams tht exhibit marked inoculum effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067747      PMCID: PMC188159          DOI: 10.1128/AAC.38.5.1112

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Effect of inoculum and of beta-lactamase on the anti-staphylococcal activity of thirteen penicillins and cephalosporins.

Authors:  L D Sabath; C Garner; C Wilcox; M Finland
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

Review 2.  Impact of the antibiotic dosage schedule on efficacy in experimental lung infections.

Authors:  R Roosendaal; I A Bakker-Woudenberg
Journal:  Scand J Infect Dis Suppl       Date:  1990

3.  Cefaclor--summary of clinical experience.

Authors:  R B Kammer; L J Short
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

4.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

5.  The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.

Authors:  P D Ellner; H C Neu
Journal:  JAMA       Date:  1981-10-02       Impact factor: 56.272

Review 6.  Killing and regrowth of bacteria in vitro: a review.

Authors:  W A Craig; S C Ebert
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 7.  Impact of the antibiotic dosage schedule on efficacy in experimental soft tissue infections.

Authors:  A U Gerber
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 8.  Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.

Authors:  G L Drusano
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 9.  Strategic antibiotic decision-making at the formulary level.

Authors:  R Quintiliani; C H Nightingale; H M Crowe; B W Cooper; R C Bartlett; G Gousse
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

10.  Effect of inoculum size and beta-lactamase production on in vitro activity of new cephalosporins against Haemophilus species.

Authors:  R R Bulger; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

View more
  11 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

3.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

4.  A semisynthetic Quillaja saponin as a drug delivery agent for aminoglycoside antibiotics.

Authors:  J Recchia; M H Lurantos; J A Amsden; J Storey; C R Kensil
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

5.  Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

Authors:  D P Nicolau; C H Nightingale; M A Banevicius; Q Fu; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

6.  Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.

Authors:  M E Klepser; M N Marangos; Z Zhu; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 8.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

9.  Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods.

Authors:  M E Klepser; M A Banevicius; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 10.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.